Boehringer jumps on KRAS cancer drug bandwagon with MD AndersonBoehringer Ingelheim has become the latest pharma company to investigate KRAS as a potential target for cancer drugs, Share XBoehringer jumps on KRAS cancer drug bandwagon with MD Andersonhttps://pharmaphorum.com/news/boehringer-jumps-on-kras-cancer-drug-bandwagon-with-md-anderson/
Boehringer announces IPF deal with Korea’s Bridge TherapeuticsBoehringer Ingelheim and South Korean biotech Bridge Biotherapeutics have announced a deal to develop the latter’s drug for Share XBoehringer announces IPF deal with Korea’s Bridge Therapeuticshttps://pharmaphorum.com/news/boehringer-announces-ipf-deal-with-koreas-bridge-therapeutics/
FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failureEli Lilly and Boehringer Ingelheim’s Jardiance was the first diabetes drug to lower the risk of cardiovascular disease Share XFDA fast-tracks Lilly/Boehringer’s Jardiance for heart failurehttps://pharmaphorum.com/news/fda-fast-tracks-lilly-boehringers-jardiance-for-heart-failure/
Boehringer adds to obesity alliance with Denmark’s GubraTwo years after they started working together, Boehringer Ingelheim and Gubra have taken their obesity collaboration to a Share XBoehringer adds to obesity alliance with Denmark’s Gubrahttps://pharmaphorum.com/news/boehringer-obesity-denmarks-gubra/
Boehringer looks to enhance COPD care with new registryBoehringer Ingelheim and Optimum Patient Care are launching a new patient registry, APEX COPD (Advancing the Patient Experience Share XBoehringer looks to enhance COPD care with new registryhttps://pharmaphorum.com/news/boehringer-enhance-copd-care-new-registry/
AbbVie gets crucial US approval for psoriasis drug SkyriziWith one eye on life without its ageing $20 billion-a-year blockbuster Humira, AbbVie has got its psoriasis drug Share XAbbVie gets crucial US approval for psoriasis drug Skyrizihttps://pharmaphorum.com/news/abbvie-gets-crucial-us-approval-for-psoriasis-drug-skyrizi/
BI chief “regrets” Brexit, but continues to invest in UKThe head of Germany’s Boehringer Ingelheim has said that he “regrets” Brexit, but reassured patients in the country Share XBI chief “regrets” Brexit, but continues to invest in UKhttps://pharmaphorum.com/news/bi-chief-regrets-brexit-but-continues-to-invest-in-uk/
Boehringer’s blockbuster Spiriva under pressure, profits downBoehringer Ingelheim has announced an increase in sales for full year 2018, but a slight decline in profits, Share XBoehringer’s blockbuster Spiriva under pressure, profits downhttps://pharmaphorum.com/news/boehringer-ingelheim-2018-sales-profits/
Boehringer files for new rare disease use for nintedanib in EU, USBoehringer Ingelheim has filed for a new use for its lung drug nintedanib in the US and Europe, Share XBoehringer files for new rare disease use for nintedanib in EU, UShttps://pharmaphorum.com/news/boehringer-files-for-new-rare-disease-use-for-nintedanib-in-eu-us/
